A Phase 2, Multicenter, Randomized, Active-controlled, Parallel-group, Dose-finding And Safety Study Of Recombinant Human Bone Morphogenetic Protein-2 (Rhbmp-2)/Calcium Phosphate Matrix (Cpm) In Subjects With Decreased Bone Mineral Density
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2015
At a glance
- Drugs Dibotermin alfa (Primary) ; Bisphosphonates; Calcium; Vitamin D analogues
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Pfizer
- 15 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 27 Jun 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.